Skip to content

The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent

Pilot Study on the Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01862198
Enrollment
27
Registered
2013-05-24
Start date
2011-09-30
Completion date
2013-08-31
Last updated
2013-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Obstruction, Disorder of Bile Duct Stent, Neoplasms

Brief summary

The purpose of this study is to investigate the feasibility and safety of endoscopic ultrasound-guided biliary drainage with a newly designed hybrid metallic stent.

Detailed description

Endoscopic ultrasound-guided biliary drainage with a fully covered metallic stent was a safe and effective method in patients with malignant biliary obstructions and had a comparatively long patency duration. Nevertheless, the significant rate of distal stent migration cannot be ignored, suggesting the need for a newly designed metallic stent for endoscopic ultrasound-guided biliary drainage.

Interventions

DEVICEEUS-guided biliary drainage with a hybrid metallic stent

EUS-guided biliary drainage with a newly designed hybrid metallic stent

Sponsors

Inje University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 20 years * The presence of an unresectable malignant biliary obstruction * Failed conventional ERCP stenting

Exclusion criteria

* Age \< 20 years * An inability to sedate the patient due to advanced heart or pulmonary diseases * A lack of informed consent

Design outcomes

Primary

MeasureTime frame
The stent patency rateUp to 48 weeks

Secondary

MeasureTime frame
Patients' survival rateUp to 48 weeks
Complication rate related to the hybrid stentsUp to 48 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026